Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Rhea-AI Summary
Alzamend Neuro (Nasdaq: ALZN) reported positive Phase II topline data for AL001 on March 26, 2026. AL001 achieved bioequivalence to lithium carbonate (101% total exposure; 97% peak) and showed ~7.8% higher whole-brain lithium with faster peak brain uptake (6.7h vs. 8.4h).
Six subjects per arm produced directional, non‑definitive results; a second Phase II in bipolar disorder is underway with topline data expected Q3 2026. Further trials depend on capital raising.
Positive
- Bioequivalence achieved: 101% total exposure and 97% peak versus lithium carbonate
- Whole-brain lithium exposure increased by ~7.8% for AL001
- Faster brain uptake: peak at 6.7 hours vs. 8.4 hours (≈1.7-hour advantage)
- 505(b)(2) pathway enabled potential due to demonstrated systemic bioequivalence
Negative
- Small sample size: 6 subjects per arm, results directional but not statistically definitive
- Next studies contingent on raising sufficient capital to start remaining Phase II trials
- Reported brain increases are numerical trends without reported statistical significance yet
Market Reaction – ALZN
Following this news, ALZN has declined 6.67%, reflecting a notable negative market reaction. Argus tracked a trough of -14.6% from its starting point during tracking. Our momentum scanner has triggered 46 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $1.40. This price movement has removed approximately $408K from the company's valuation. Trading volume is exceptionally heavy at 10.0x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
ALZN gained 7.22% on positive AL001 Phase II data while closest momentum peer ADIL was up modestly and several other biotech peers were flat to down, indicating a stock-specific move rather than a broad sector rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2025-11-19 | Phase II completion | Positive | -5.3% | Completion of clinical portion of Phase II AL001 brain/blood PK study at MGH. |
| 2025-05-29 | Phase II dosing | Positive | +63.9% | Dosing of first patient in Phase II AL001 trial with strong efficacy potential messaging. |
| 2025-05-19 | First patient enrolled | Positive | +5.9% | Enrollment of first patient in Phase II AL001 healthy-subject trial at MGH. |
| 2025-05-13 | Phase II initiation | Positive | -18.8% | Initiation of first Phase II AL001 trial comparing brain and blood PK to lithium carbonate. |
| 2025-03-25 | Alzheimer’s trial plan | Positive | -1.0% | Announcement of planned Phase II AL001 Alzheimer’s trial start at MGH in Q4 2025. |
Clinical-trial headlines for AL001 have produced mixed reactions: some strong rallies alongside several selloffs on otherwise positive updates, suggesting inconsistent trading responses to similar news.
Over the past year, Alzamend has issued a series of AL001 Phase II "Lithium in Brain" updates tied to Massachusetts General Hospital. These include trial initiation in Alzheimer’s patients on 2025-03-25, subsequent Phase II starts and first-patient milestones in May 2025 with moves up to +63.86%, and completion of the clinical portion on 2025-11-19 (stock fell 5.33%). Today’s positive topline data in healthy subjects continues that clinical narrative as the program transitions from setup and enrollment milestones to pharmacokinetic readouts.
Historical Comparison
In the past year, ALZN released 5 AL001 clinical-trial updates with an average move of 8.92%. Today’s 7.22% reaction to positive Phase II topline data is broadly in line with prior same-tag volatility.
Clinical updates show a steady AL001 progression: Alzheimer’s Phase II planning, trial initiation, first enrollment and dosing, completion of the healthy-subject Phase II portion, and now detailed topline brain/blood exposure results guiding subsequent indication-specific Phase II studies.
Market Pulse Summary
The stock is down -6.7% following this news. A negative reaction despite positive topline findings would fit ALZN’s history of inconsistent responses to AL001 clinical updates, where several upbeat trial milestones still saw declines. Traders may focus on small sample size, preliminary nature of brain data, or broader financing and listing risks highlighted in recent filings. Given prior average clinical-trial moves of 8.92%, any outsized downside could reflect sentiment on balance-sheet and execution risk rather than this single dataset.
Key Terms
bioequivalence medical
AI-generated analysis. Not financial advice.
- Bioequivalence Confirmed: AL001 delivered
101% of total lithium blood exposure and97% of peak lithium levels vs. standard lithium carbonate - Superior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions, including whole brain
- Faster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonate
Phase II Topline Results
- AL001 Achieves Bioequivalence with Standard Lithium Carbonate:
- The
U.S. Food and Drug Administration (the "FDA") requires a new formulation to deliver between80% to125% of the reference drug to the bloodstream to support equivalent systemic safety. AL001 delivered101% of total lithium exposure and97% of peak lithium levels compared to standard lithium carbonate, which are both squarely within the required FDA range. Achieving bioequivalence supports a Section 505(b)2 new drug application submission for safety, potentially mitigating non-clinical requirements.
- The
- Superior Brain Penetration Across all 26 Measured Regions, Including Whole Brain:
- Using a one-of-a-kind Tesla head coil that provides advanced magnetic resonance imaging ("MRI") and magnetic resonance spectroscopy ("MRS") neuroimaging, researchers quantified lithium in 25 discrete brain regions as well as the whole brain. AL001 showed numerically higher lithium concentrations in every single region vs. standard lithium carbonate, including the hippocampus (memory), entorhinal cortex (early Alzheimer's target), cingulate gyrus (cognition), amygdala and accumbens regions. Maximum whole-brain lithium exposure increased ~
7.8% for AL001 compared to lithium carbonate. A consistent directional increase across all measured brain regions is a compelling signal, and confirmation is already underway; the second of five planned Phase II trials, enrolling a total of 30 patients across the full program, is already underway at MGH.
- Using a one-of-a-kind Tesla head coil that provides advanced magnetic resonance imaging ("MRI") and magnetic resonance spectroscopy ("MRS") neuroimaging, researchers quantified lithium in 25 discrete brain regions as well as the whole brain. AL001 showed numerically higher lithium concentrations in every single region vs. standard lithium carbonate, including the hippocampus (memory), entorhinal cortex (early Alzheimer's target), cingulate gyrus (cognition), amygdala and accumbens regions. Maximum whole-brain lithium exposure increased ~
- Faster Brain Uptake Results in Earlier Peak Concentration:
- AL001 achieved peak brain lithium concentrations at 6.7 hours compared to 8.4 hours for standard lithium carbonate, resulting in a potential ~1.7-hour advantage. Faster brain uptake could have meaningful implications for therapeutic onset and dosing optimization, which will be evaluated in subsequent studies.
- Second Phase II Clinical Trial Already Underway at MGH:
- In this first study, brain tissue measurements were conducted in six subjects per arm, which is a sample size that produces directionally meaningful, but not yet statistically definitive, results. The ~
7.8% whole-brain lithium trend is worthy of further investigation. To that end, Alzamend has initiated its second Phase II "Lithium in Brain" clinical trial at MGH, this time in patients with BD, with topline data expected in the third quarter of 2026. The third, fourth, and fifth studies in the program enrolling patients with MDD, PTSD and Alzheimer's, respectively, are anticipated to begin in the latter half of 2026, subject to raising sufficient capital. Alzamend believes that results across all five studies, totaling 30 patients, will be adequate to establish statistical significance and advance AL001 toward further regulatory milestones.
- In this first study, brain tissue measurements were conducted in six subjects per arm, which is a sample size that produces directionally meaningful, but not yet statistically definitive, results. The ~
"These data mark a pivotal advancement in the development of AL001," said Stephan Jackman, CEO of Alzamend. "We have clinical evidence that AL001 shows equivalent delivery of lithium in the bloodstream compared to standard lithium carbonate capsules, which is a key regulatory safety measure. And the brain data, while preliminary, show a consistent increase providing higher lithium in every brain region we measured. This can permit lower systemic doses to achieve efficacy thereby providing an enhanced safety profile. Combined with the faster brain uptake, we believe AL001 has a meaningfully differentiated profile compared to conventional lithium; one that could benefit the 43+ million Americans afflicted with Alzheimer's, BD, MDD and PTSD."
AL001: A Differentiated Lithium Therapy for a Large Unmet Need
Although lithium has remained the gold standard treatment for BD for more than 55 years, its clinical utility is constrained by a narrow therapeutic window and the need for regular therapeutic drug monitoring ("TDM") to manage renal, thyroid, and other systemic toxicity risks. AL001 is Alzamend's patented ionic cocrystal formulation of lithium combined for delivery with L-proline and salicylate, which is designed to deliver a full therapeutic amount of lithium to the brain with less systemic exposure than lithium carbonate, potentially enabling a safer, better-tolerated therapy across Alzheimer's, BD, MDD and PTSD.
About this Study
The study employed a randomized crossover design with multiple six-subject cohorts. Participants were assigned to one of two sequences: AB (AL001 then lithium carbonate) or BA (lithium carbonate then AL001). Each treatment period consisted of 14 days of three-times-daily ("TID") dosing, separated by a 14-day washout.
On Days 14–15, participants underwent 24-hour pharmacokinetic blood sampling alongside advanced MRI and MRS neuroimaging, a first-of-its-kind methodology. The MRI and MRS neuroimaging methods were developed by the lab of Dr. Ovidiu Andronesi, the study's principal investigator, Associate Professor of Radiology at Harvard University and the Director of Multinuclear Metabolic Imaging, Martinos Center for Biomedical Imaging, Department of Radiology, MGH, Harvard Medical School. The study also incorporated a specialized, engineered head coil developed by Tesla Dynamic Coils BV, designed to enable high-resolution, whole-brain lithium imaging. This approach enabled simultaneous quantification of lithium concentrations in blood and brain including individual structures, as well as assessment of brain and individual brain structure chemistry, metabolism, and biomarker effects.
The study specifically evaluated AL001's ability to enhance lithium delivery to targeted brain regions while reducing systemic exposure, an approach designed to address the long-standing safety and tolerability limitations associated with traditional lithium salts. The results from the study confirmed that AL001 matches blood levels of standard lithium carbonate, the reference drug, addressing FDA regulatory requirements for a new drug formulation, as well as providing a differentiated, potential dose-sparing benefit profile for patients.
About Alzamend Neuro
Alzamend is a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001, a patented ionic cocrystal delivering lithium with salicylate and L-proline designed to improve brain delivery and safety compared to conventional lithium, and ALZN002, a patented cell-based therapeutic vaccine designed to restore the immune system's ability to clear beta-amyloid. The latter is a next-generation active-immunity approach offering potential advantages in dosing frequency and cost compared to approved passive-immunity antibody therapies. Both candidates are exclusively licensed from the University of South Florida Research Foundation under royalty-bearing worldwide licenses.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend's business and financial results are included in Alzamend's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-trial-of-al001-lithium-in-brain-study-al001-achieves-bioequivalence-and-demonstrates-superior-brain-delivery-across-all-measured-brain-regions-302725991.html
SOURCE Alzamend Neuro, Inc.
FAQ
What did Alzamend (ALZN) announce on March 26, 2026 about AL001?
Does AL001 meet FDA bioequivalence requirements for ALZN's regulatory path?
How much greater was brain lithium with AL001 compared to lithium carbonate in ALZN's study?
When will ALZN report additional Phase II results for AL001 and what trials are planned?
What does the faster brain uptake of AL001 mean for patients and dosing?
